Form 4 for STLN Starling Oncology, Inc.
Accepted 2026-08-24 17:11:12 ET · period of report 2026-08-21 · accession 0001079973-26-001175 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-08-24 17:11 | 2026-08-21 | STLN | Hively Brad | Dir | S - Sale | $6.51 | -298.9K | 412.0K | -42% | -$1.95M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-21 | S | D | 298,853 | $6.51 | 411,976 | D | — | — | (F1) Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.37 to $6.75 per share. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided. |